QTTB - Q32 Bio Inc. Analyst Forecast Prices
Q32 Bio Inc. (QTTB) maintains a biotechnological foundation in autoimmune pathologies currently in the testing phase, while its financial stability, reaching 39.29, depends on external funding. The stock price history helps track this process. Q32 Bio Inc. (QTTB) relies on an experienced team of immunologists with strict budget controls and an extensive network of specialized warehouses, ensuring seamless component delivery and high returns.
Analytical breakdowns for Q32 Bio Inc. (QTTB)
- market value and analyst target forecast:
- market capitalization statistics:
- book capitalization information:
- business debt structure and liquidity details:
Aggregate Debt to Equity Q32 Bio Inc.|QTTB - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital q32bio.com|QTTB - Company Aggregate Debts|Debts to Book Capitalization Q32 Bio Corp|QTTB - Company Long-Term Debt|Company Short-Term Loans and Borrowings Q32 Bio|Quick Liquidity Indicator q32bio.com
- earnings and market ratios statistics:
QTTB - Net Profit|Projected Future Earnings Q32 Bio Inc.|QTTB - Price to Earnings Ratio|Future Price to Earnings Multiple q32bio.com|QTTB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Q32 Bio Corp|QTTB - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Q32 Bio|QTTB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months q32bio.com|QTTB - Net earnings per share growth this year|Earnings growth forecast for next year Q32 Bio Inc.
General company analysis:QTTB Q32 Bio Inc
The stability of protein supplies through the diversified laboratories of Q32 Bio Inc. (QTTB) minimizes operational risks, which forms the basis of the asset's fundamental value. The average expert consensus on the stock synthesizes confirmed financial facts, reflecting the dynamics of target prices as market multiples shift; the regular convergence of the price with this trajectory confirms a fair valuation but limits the potential for explosive growth.
Competitors of Q32 Bio Inc.
argenx.com (ARGX) - Analyst Target Range|BioNTech - Consensus Target|Analyst Forecast Prices ABVX (Abivax SA)|ADMA: Consensus Target|Protagonist Corp - Analyst Forecast Prices|IMVT: Analyst Consensus Forecast|KNSA (kiniksa.com) - Price Target Chart|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|JBIO - Price Target Chart|Analyst Target Range Aclaris Therapeutics, Inc (ACRS)|KYTX (Kyverna Therapeutics) - Consensus Target|TLSA (tizianalifesciences.com) - Price Target Chart|Consensus Target CABA|VTYX: Fair Value Consensus|Analyst Consensus Forecast THTX|Price Target Chart AVTX (Avalo Therapeutics Inc)|Analyst Consensus Forecast ELDN (Eledon Pharmaceuticals)|Analyst Median Target agenusbio.com (AGEN)|CLYM - Price Target Chart|Average Forecast Price zurabio.com|ATYR (aTyr) - Consensus Target|Adagene Inc. - Fair Value Consensus|IMA (ImageneBio) - Analyst Consensus Forecast|Shattuck Therapeutics (STTK) - Analyst Median Target|Price Target Chart Equillium, Inc. (EQ)|connectbiopharm.com - Broker Consensus Forecast|Analyst Consensus Forecast IMUX (Immunic)|ATRA - Consensus Target|IFRX: Consensus Target|Analyst Median Target x4pharma.com XFOR|adicetbio.com (ACET) - Price Target Chart|Analyst Target Range Celularity CELU|Consensus Target INMB|BRNS (Barinthus Biotherapeutics Corp) - Analyst Forecast Prices|Consensus Target KZR (Kezar Life Sciences)|Analyst Forecast Prices SABS|Analyst Consensus Forecast AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd - Price Target Chart|GOVX - Price Target Chart|Forecast Levels Chart EDSA|IBIO: Analyst Consensus Forecast|Carisma Therapeutics Inc. - Fair Value Consensus|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|Analyst Consensus Forecast Bolt Bio|Price Target Chart HCW Biologics Inc. (HCWB)|APVO (aptevotherapeutics.com) - Fair Value Consensus|Price Target Chart AIM ImmunoTech AIM|ADTX - Consensus Target|GRI Bio - Analyst Consensus Forecast|XRTX - Analyst Consensus Forecast|HIND (ReShape Lifesciences) - Consensus Target|Revelation Biosciences Corp - Fair Value Consensus|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|scinai.com (SCNI) - Analyst Median Target|Price Target Chart CalciMedica, Inc. (CALI)|Consensus Target affimed.com AFMD|Price Target Chart Allakos ALLK|HOOK - Consensus Target|IGMS: Consensus Target|ITOS - Analyst Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|Broker Consensus Forecast TCBP|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
